Sleep-promoting and anxiety-resisting medicine as well as preparation method and application thereof
Through a combination of traditional Chinese medicine ingredients such as Astragalus, it is prepared into granules, which solves the treatment problems of spleen deficiency insomnia and anxiety, and achieves the effect of improving sleep quality and reducing Western medicine dependence. It is suitable for the treatment of spleen deficiency insomnia and anxiety.
Patent Information
- Application Number
- CN202411130465.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-16
- Publication Date
- 2024-11-08
AI Technical Summary
Existing insomnia treatment methods, especially sedative hypnosis drugs, are prone to problems such as drug dependence, addiction and rebound during long-term use or abuse, and Chinese medicine compositions used to treat spleen deficiency insomnia are relatively lacking and difficult to meet clinical needs.
Using a combination of traditional Chinese medicine ingredients including Astragalus, Codonopsis, Codonopsis pilosula, Tangerine peel, Ophiopogon japonicus, Atractylodes macrocephala, Atractylodes macrocephala, Huangbo, Shenqu, licorice, Schisandra chinensis, prickly nucleus, bitter almond, peony bark and Anaestheticum, through decoction and The spray drying process is prepared into granules, which are used to treat spleen deficiency insomnia and anxiety.
This drug can effectively improve the sleep quality and psychosomatic symptoms of patients with spleen deficiency type insomnia, reduce the use of Western medicine, improve the efficacy of patients who have taken Western medicine before diagnosis, and significantly reduce the variety and dosage of psychiatric drugs.
Smart Images

Figure BDA0004997672370000081 
Figure BDA0004997672370000103 
Figure BDA0004997672370000104
Abstract
Description
Technical Field
[0001] The invention belongs to the field of traditional Chinese medicine, and specifically relates to a hypnotic and anti-anxiety drug and a preparation method and application thereof. Background Art
[0002] With economic development and the accelerated pace of life, insomnia has become the second largest mental disorder in the world. A 2017 meta-analysis of the epidemiology of insomnia in China showed that the incidence of insomnia among adults in my country reached 15%, a significant increase compared to the 9.2% incidence in 2008. The increasing incidence of insomnia has put forward higher requirements for more efficient diagnosis and treatment in the clinical practice of insomnia. At present, the diagnosis and treatment methods for insomnia are still relatively scarce. Several international guidelines mention sedatives, hypnotics and psychotropic drugs as first-line drugs for the treatment of insomnia. Although these drugs have certain effects in improving sleep quality and improving sleep efficiency, they are recommended for short-term temporary use. Long-term use or abuse of sedatives and hypnotics can cause difficult clinical problems such as drug dependence, addiction, rebound, and the need for lifelong medication.
[0003] Traditional Chinese medicine is based on the holistic concept and the characteristics of individualized syndrome differentiation and treatment. It can play an important role in the diagnosis and treatment of insomnia. It has the advantages of precision, individualization, and few adverse reactions, and has good application prospects. Spleen deficiency insomnia is a common type of insomnia in clinical practice, but there is a lack of Chinese medicine compositions for the treatment of spleen deficiency insomnia in clinical practice. Therefore, it is necessary to develop a Chinese medicine composition that can effectively treat spleen deficiency insomnia to meet the clinical medication needs. Summary of the invention
[0004] The first purpose of the present invention is to provide a hypnotic and antianxiety drug. The second purpose of the present invention is to provide a method for preparing the hypnotic and antianxiety drug. The third purpose of the present invention is to provide an application of the hypnotic and antianxiety drug.
[0005] According to the first aspect of the present invention, a hypnotic and anti-anxiety drug is provided, the effective ingredients of which include the following raw materials in parts by mass: 10-50 parts of Astragalus, 10-15 parts of Cimicifuga, 10-30 parts of Codonopsis, 10-30 parts of Tangerine Peel, 10-30 parts of Ophiopogon, 10-30 parts of Atractylodes, 10-30 parts of Atractylodes, 10-30 parts of Atractylodes, 5-45 parts of Phellodendron, 10-50 parts of Shenqu, 5-20 parts of Angelica, 5-30 parts of Licorice, 5-15 parts of Schisandra, 10-30 parts of Alpinia oxyphylla, 5-30 parts of Bitter Apricot, 5-30 parts of Dry Ginger, 10-20 parts of Paeonia Suffruticosa, and 10-30 parts of Anemarrhena.
[0006] The present invention believes that the spleen and stomach qi are full, the spleen rises and the stomach descends, each performing its own duties, so that the spleen and stomach can be sufficient in terms of source transformation, the qi and blood circulation is unobstructed, the vital energy and the qi of the five internal organs are nourished, and the spleen rises and wakes up, and the stomach descends and sleeps. If the spleen and stomach are damaged by diet and fatigue, the qi and blood biochemical process is weak, the spleen and stomach rise and fall abnormally, and the qi rise and fall imbalance is prone to insomnia for a long time; at the same time, the spleen is in the mind for thinking, if you usually think too much, thinking hurts the spleen, and spleen deficiency leads to worry, which also consumes qi and blood, and the essence cannot nourish the mind and the mind is not guarded, so spleen deficiency type insomnia will be accompanied by emotional instability or irritable anxiety symptoms to varying degrees, and spleen deficiency often directly causes anxiety.
[0007] In the formula, astragalus is sweet and slightly warm, enters the spleen and lung meridians, replenishes the middle qi, and strengthens the exterior, so it is the main drug. It is combined with codonopsis, licorice, and atractylodes to replenish qi and strengthen the spleen as the assistant drug. Angelica nourishes blood and harmonizes the camp, and assists codonopsis and astragalus to replenish qi and nourish blood; tangerine peel and dried ginger regulate qi and harmonize the stomach, and dried ginger and licorice are matched to strengthen spleen yang. Cimicifuga raises yang and lifts the sunken, and assists the main drug astragalus to lift the sunken middle qi. Licorice is the guiding drug to harmonize the various drugs. Atractylodes, Phellodendron, Shenqu, Ophiopogon, Schisandra, Paeonia suffruticosa, and Anemarrhena asphodeloides take into account nourishing yin and clearing heat. Paeonia suffruticosa and Anemarrhena asphodeloides reduce virtual fire and clear blood heat, especially suitable for anxiety and insomnia caused by spleen deficiency and damp-heat syndrome. At the same time, Paeonia suffruticosa and Anemarrhena asphodeloides have a good anti-anxiety effect when used together with astragalus, Atractylodes lancea and Atractylodes. Alpinia oxyphylla and bitter apricot kernel nourish the lungs and kidneys to strengthen the spleen and earth. The whole prescription is rigorously formulated, based on the principles of ascending yang and replenishing qi, nourishing yin and clearing heat, replenishing the acquired constitution while taking into account the innate constitution, and using both invigorating the spleen and replenishing qi and nourishing yin and clearing heat, so that the spleen and stomach are sufficient in terms of transformation, the circulation of qi and blood is unobstructed, and the primordial qi and the qi of the five internal organs are replenished, so it can effectively treat insomnia; at the same time, it nourishes the mind and keeps the mind, so it can effectively treat anxiety. Therefore, this prescription is particularly suitable for the treatment of insomnia and anxiety of spleen deficiency type.
[0008] The raw material sources of the present invention are as follows:
[0009] Astragalus: The root of Astragalus memeranaceus (Fisch.) Bge. Var. mongholicus (Bge.) Hsiao or A. membranaceus (Fisch.) Bge. of the genus Astragalus in the Leguminosae family.
[0010] Cimicifuga: The rhizome of Cimicifuga heracleifolia Kom, Cimicifuga dahurica (Turez.) maxim. or Cimicifuga foetida L., plants of the Ranunculaceae family.
[0011] Codonopsis: The root of Codonopsis pilosula (Franch.) Nannf., C.pilosula Nannf.var. (Nannf.) LTShen or C.tangshen Oliv. of the Campanulaceae family.
[0012] Tangerine peel: the dried mature peel of Citrus reticulata Blanco and its cultivated varieties.
[0013] Ophiopogon japonicus: The dried tuberous root of Ophiopogon japonicus (Thunb.) Ker-Gawl., a plant of the Liliaceae family.
[0014] Atractylodes: The dried rhizome of Atractylodes lancea (Thunb.) DC. or Atractylodes chinensis (DC.) Koidz., plants of the genus Atractylodes in the Asteraceae family.
[0015] Atractylodes: The rhizome of Atractylodes macrocephala Koidz, a plant of the genus Atractylodes in the Asteraceae family.
[0016] Phellodendron: The dried bark of Phellodendron chinense Schneid. or Phellodendron amurense Rupr. of the Rutaceae family.
[0017] Shenqu: A fermented koji made by adding flour or bran to Polygonum hydropiper, Artemisia annua, almond paste, adzuki bean, and fresh Xanthium sibiricum.
[0018] Angelica: The root of Angelica sinensis (Oliv) Diels., a plant of the Apiaceae family.
[0019] Licorice: The dried roots and rhizomes of Glycyrrhiza uralensis Fisch., Glycyrrhiza inflata Bat. or Glycyrrhiza glabra L., plants of the genus Glycyrrhiza in the family Leguminosae.
[0020] Schisandra: The ripe fruit of Schisandra chinesis (Turcz.) Ball or Schisandra sphenanthera rehd. et Wils., a plant of the genus Schisandra in the family Schisandraceae.
[0021] Alpinia oxyphylla Miq.: the fruit of Alpinia oxyphylla Miq., a plant of the genus Alpinia in the Zingiberaceae family.
[0022] Bitter almond: the ripe fruit of Prunus armeniaca L.var.ansu Maxim. Siberian apricot P.sibirica L., Northeast apricot P.mandshurica (Maxim) Koehne or apricot P.armeniaca L., a plant of the Rosaceae family.
[0023] Dried ginger: the dried rhizome of ginger, Zingiber officinale Rosc., a plant of the Zingiberaceae family.
[0024] Peony bark: the dried root bark of Paeonia suffruticosa Andr., a plant of the genus Paeonia in the family Paeoniaceae.
[0025] Anemarrhena asphodeloides: The dried rhizome of Anemarrhena asphodeloides Bge., a plant of the genus Anemarrhena in the Liliaceae family.
[0026] In some embodiments, the effective ingredients include the following raw materials in parts by mass: 30 parts of Astragalus, 15 parts of Cimicifuga, 15 parts of Codonopsis, 15 parts of Tangerine Peel, 15 parts of Ophiopogon, 15 parts of Atractylodes, 15 parts of Atractylodes, 10 parts of Phellodendron, 30 parts of Shenqu, 10 parts of Angelica, 15 parts of Licorice, 10 parts of Schisandra, 15 parts of Alpinia oxyphylla, 15 parts of Apricot Kernel, 5 parts of Dry Ginger, 15 parts of Paeonia Suffruticosa, and 15 parts of Anemarrhena.
[0027] In some embodiments, the active ingredients also include at least one of the following raw materials in parts by weight: 15-30 parts of Angelica dahurica, 5-10 parts of Notopterygium wilfordii, 5-10 parts of Saposhnikovia divaricata, 15-30 parts of Rehmannia glutinosa, 15-30 parts of Gypsum Fibrosum, 30-60 parts of Radix Trichosanthis, 15-30 parts of Magnolia officinalis, and 15-30 parts of Apricot kernel.
[0028] Generally speaking, if there are symptoms such as limb pain, shoulder and back pain caused by the invasion of wind, cold and dampness, add Duhuo, Qianghuo and Saposhnikovia divaricata; if there are obvious symptoms such as dry mouth, fatigue, back pain, weak legs, and fever in the five hearts, add Shengdihuang; if there are fever, thirst, and headache, toothache, swollen and painful gums or swollen and painful sores caused by hyperactivity of stomach fire, add Gypsum and Trichosanthes; if there are symptoms such as constipation, phlegm, cough, chest tightness, vomiting, and loose stools caused by food stagnation or cold and dampness, add Magnolia officinalis; if there are symptoms such as chest tightness, shortness of breath, and difficulty breathing at night, add bitter almonds.
[0029] In some embodiments, the licorice root is roasted licorice root.
[0030] In some embodiments, pharmaceutically acceptable excipients may also be added.
[0031] In some embodiments, the auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption enhancer, an adsorption carrier, a surfactant, and a lubricant.
[0032] In some embodiments, the dosage form of the drug is granules, decoction, paste, powder, tablet, pill or capsule.
[0033] According to a second aspect of the present invention, a method for preparing the above-mentioned hypnotic and antianxiety drug is provided. When the drug is in the form of granules, the preparation method comprises the following steps:
[0034] (1) The above raw material drug is decocted with water twice. For the first decoction, water equivalent to 10 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and the first decoction and the residue are obtained after separation; for the second decoction, the residue obtained after the first decoction is taken, water equivalent to 8 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and the second decoction and the residue are obtained after separation; the first decoction and the second decoction are combined and filtered to obtain a filtrate;
[0035] (2) the filtrate obtained in step (1) is concentrated under reduced pressure to obtain a clear paste, wherein the relative density of the clear paste can be based on the actual measured value;
[0036] (3) adding auxiliary materials to the clear paste obtained in step (2) and spray drying to obtain a dry paste powder, wherein the spray drying process parameters are: inlet air temperature 165-185° C., outlet air temperature 80-95° C.;
[0037] (4) adding auxiliary materials to the dry paste powder obtained in step (3), and mixing them in a mixer for 30 minutes to obtain a mixed powder;
[0038] (5) adding a 90% by volume ethanol-water solution to the mixed powder obtained in step (4) to prepare a soft material, and granulating the soft material through a 12-mesh sieve to obtain wet granules;
[0039] (6) Drying the wet granules obtained in step (5) at 65°C to obtain
[0040] According to a third aspect of the present invention, there is provided use of the above-mentioned hypnotic and antianxiety drugs in the preparation of drugs for treating spleen deficiency-type insomnia and / or anxiety and / or depression.
[0041] According to a fourth aspect of the present invention, there is provided use of the above-mentioned hypnotic and antianxiety drugs in the preparation of drugs for treating chronic insomnia and / or anxiety and / or depression of spleen deficiency type.
[0042] The beneficial effects of the present invention include:
[0043] (1) Clinical trials have shown that the hypnotic and anti-anxiety drugs of the present invention can effectively treat spleen deficiency insomnia, and have a good therapeutic effect on spleen deficiency insomnia of different severity. They can improve the clinical efficacy of patients who have taken Western medicine before diagnosis and reduce the types and dosages of psychiatric drugs in the original Western medicine treatment plan.
[0044] (2) Clinical trials have shown that the hypnotic and anti-anxiety drugs of the present invention can effectively improve the sleep quality and psychosomatic symptoms of patients with chronic insomnia of spleen deficiency type. BRIEF DESCRIPTION OF THE DRAWINGS
[0045] Figure 1 This is a case screening diagram in Experiment 1 of the present invention. DETAILED DESCRIPTION
[0046] The present invention is further described in detail below in conjunction with specific examples, but the embodiments of the present invention are not limited thereto. The materials involved in the following examples can all be obtained from commercial channels.
[0047] Example 1
[0048] The preparation method of the sleeping and anti-anxiety granules of this embodiment comprises the following steps:
[0049] (1) Weigh 30g of Astragalus, 15g of Cimicifuga, 15g of Codonopsis, 15g of Citrus reticulata, 15g of Radix Ophiopogonis, 15g of Atractylodes, 15g of Atractylodes, 15g of Phellodendron, 10g of Shenqu, 30g of Radix Angelicae Sinensis, 10g of Radix Glycyrrhizae Preparata, 10g of Schisandrae Chinensis, 15g of Alpinia oxyphylla, 15g of Apricot Kernel, 5g of Dry Ginger, 15g of Paeonia suffruticosa, and 15g of Rhizoma Anemarrhenae.
[0050] (2) The above raw material drug is decocted twice with water. For the first decoction, water equivalent to 10 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours. After separation, a first decoction and a medicinal residue are obtained; for the second decoction, the medicinal residue obtained after the first decoction is taken, water equivalent to 8 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours. After separation, a second decoction and a medicinal residue are obtained; the first decoction and the second decoction are combined and filtered to obtain a filtrate.
[0051] (3) The filtrate obtained in step (2) is concentrated under reduced pressure (vacuum degree -0.08 MPa, temperature 70°C) to a clear paste with a relative density of 1.15 (60°C).
[0052] (4) adding maltodextrin accounting for 10% of the total weight of the API to the clear paste obtained in step (3) and spray drying the mixture to obtain a dry paste powder, wherein the spray drying process parameters are: inlet air temperature of 170° C. and outlet air temperature of 90° C.
[0053] (5) Add an appropriate amount of maltodextrin to the dry paste powder obtained in step (4), and mix it in a mixer for 30 minutes to make it uniform, to obtain a mixed powder.
[0054] (6) Adding a 90% by volume ethanol-water solution to the mixed powder obtained in step (5) to prepare a soft material, and granulating the soft material through a 12-mesh sieve to obtain wet granules.
[0055] (7) Dry the wet granules obtained in step (6) at 65°C to obtain the product. Store the granules in sealed packages of 6 g each. Take the granules three times a day, one package at a time.
[0056] Example 2
[0057] The preparation method of the sleeping and anti-anxiety decoction of this embodiment comprises the following steps:
[0058] (1) Weigh 30g of Astragalus, 15g of Cimicifuga, 15g of Codonopsis, 15g of Citrus reticulata, 15g of Radix Ophiopogonis, 15g of Atractylodes, 15g of Atractylodes, 15g of Phellodendron, 10g of Shenqu, 30g of Radix Angelicae Sinensis, 10g of Radix Glycyrrhizae Preparata, 10g of Schisandrae Chinensis, 15g of Alpinia oxyphylla, 15g of Apricot Kernel, 5g of Dry Ginger, 15g of Paeonia suffruticosa, and 15g of Rhizoma Anemarrhenae.
[0059] (2) The above raw material medicine is decocted with water twice. For the first decoction, water equivalent to 10 times the total mass of the raw material medicine is added, heated to boiling, and kept at a slight boiling for 1.5 hours. After separation, a first decoction and a medicinal residue are obtained; for the second decoction, the medicinal residue obtained after the first decoction is taken, water equivalent to 8 times the total mass of the raw material medicine is added, heated to boiling, and kept at a slight boiling for 1.5 hours. After separation, a second decoction and a medicinal residue are obtained; the first decoction and the second decoction are combined, and the filtrate is obtained by filtration.
[0060] The Chinese medicine decoction prepared in this embodiment is a dose of about 200 mL.
[0061] Example 3
[0062] The preparation method of the hypnotic and anti-anxiety decoction of this embodiment is similar to that of embodiment 2, except that, in step (1), 15 g of Astragalus, 10 g of Cimicifuga, 15 g of Codonopsis, 10 g of Citrus reticulata, 15 g of Ophiopogon japonicus, 10 g of Atractylodes, 10 g of Atractylodes macrocephala, 5 g of Phellodendron, 20 g of Shenqu, 10 g of Angelica sinensis, 10 g of Radix Glycyrrhizae Preparata, 5 g of Schisandrae Chinensis, 10 g of Alpinia oxyphylla, 5 g of Apricot kernel, 10 g of Dry ginger, 10 g of Paeonia suffruticosa, and 15 g of Anemarrhena asphodeloides.
[0063] The Chinese medicine decoction prepared in this embodiment is a dose of about 200 mL.
[0064] Example 4
[0065] The preparation method of the hypnotic and anti-anxiety decoction of this embodiment is similar to that of embodiment 2, except that, in step (1), 10 g of Astragalus, 10 g of Cimicifuga, 10 g of Codonopsis, 10 g of Citrus reticulata, 10 g of Radix Ophiopogonis, 10 g of Atractylodes, 10 g of Atractylodes, 10 g of Phellodendron, 10 g of Shenqu, 5 g of Angelica, 5 g of Licorice, 5 g of Schisandra, 10 g of Alpinia oxyphylla, 10 g of Apricot kernel, 5 g of Dry ginger, 10 g of Paeonia suffruticosa, and 10 g of Rhizoma Anemarrhenae are weighed.
[0066] The Chinese medicine decoction prepared in this embodiment is a dose of about 200 mL.
[0067] Example 5
[0068] The preparation method of the hypnotic and anti-anxiety decoction of this embodiment is similar to that of embodiment 2, except that, in step (1), 50 g of Astragalus, 15 g of Cimicifuga, 30 g of Codonopsis, 30 g of Citrus reticulata, 30 g of Radix Ophiopogonis, 30 g of Atractylodes, 30 g of Atractylodes, 45 g of Phellodendron, 50 g of Shenqu, 20 g of Angelica, 30 g of Licorice, 15 g of Schisandra, 30 g of Alpinia oxyphylla, 30 g of Apricot kernel, 30 g of Dry ginger, 20 g of Paeonia suffruticosa, and 30 g of Rhizoma Anemarrhenae are weighed.
[0069] The Chinese medicine decoction prepared in this embodiment is a dose of about 200 mL.
[0070] In order to explore the therapeutic effect of the hypnotic and antianxiety drug of the present invention on spleen deficiency type insomnia, the following clinical trials were conducted.
[0071] Test 1
[0072] 1. Materials and methods
[0073] 1.1 Source of case data
[0074] From January 2018 to August 2022, outpatient cases diagnosed with insomnia by outpatient physicians with attending titles of or above in the Department of Psychological Sleep of Guangdong Provincial Hospital of Traditional Chinese Medicine were included. The outpatient records of 102 outpatients were evaluated by standardized and objective scales before and after taking the decoction. The remaining records were not included due to the lack of standardized evaluation before and after treatment and the large discrepancy between the prescription used and the decoction. See details as follows Figure 1 .
[0075] 1.1.1 Diagnostic criteria for insomnia (refer to the International Classification of Sleep Disorders (3rd Edition) (ICSD-3) (2017 Edition):
[0076] ICSD-3 diagnostic criteria for chronic insomnia: must meet (1)-(6) at the same time:
[0077] (1) The patient complains, or the parents or caregivers discover, one or more of the following symptoms:
[0078] Difficulty falling asleep.
[0079] Difficulty maintaining sleep.
[0080] Waking up earlier than you would like.
[0081] Refuse to go to bed on an appropriate schedule.
[0082] Difficulty falling asleep without intervention from a parent or caregiver.
[0083] (2) The patient complains, or the parents or caregivers discover, one or more of the following symptoms related to difficulty sleeping at night:
[0084] Fatigue and malaise.
[0085] Impaired attention, concentration and memory.
[0086] Social, family, and occupational functioning are impaired, and academic performance declines.
[0087] Mood swings or irritability.
[0088] Daytime sleepiness.
[0089] Behavioral problems (such as hyperactivity, impulsiveness, or aggressive behavior).
[0090] Low enthusiasm, energy, or motivation.
[0091] Increased tendency to errors and accidents.
[0092] Excessive concern or dissatisfaction with sleep.
[0093] (3) The complaint of difficulty sleeping / awakening cannot be simply explained by insufficient sleep opportunity (e.g., sufficient sleep time allocated) or a poor sleeping environment (e.g., safe, dark, quiet, and comfortable environment).
[0094] (4) Sleep disturbances and related daytime symptoms occur at least three times a week.
[0095] (5) Sleep disturbance and related daytime symptoms persist for at least 3 months.
[0096] (6) The sleep / wake difficulty is not better explained by another sleep disorder.
[0097] Diagnostic criteria for short-term insomnia: meeting criteria (1) to (3) and (6) for chronic insomnia, but with a duration of less than 3 months and / or symptoms occurring less than 3 times per week.
[0098] 1.1.2 Standards for TCM Syndrome Differentiation
[0099] With reference to the relevant discussions in "Treatise on Spleen and Stomach", the Huangqi Renshen Decoction syndrome is proposed to be the spleen and stomach qi deficiency syndrome, and the TCM syndrome differentiation standard is formulated with reference to the spleen and stomach qi deficiency syndrome in the "Terminology of Clinical Diagnosis and Treatment of Traditional Chinese Medicine" and the "Guidelines for Clinical Trials of New Chinese Medicines for the Treatment of Insomnia".
[0100] Diagnostic criteria:
[0101] Main symptoms: early awakening, difficulty falling asleep, easy awakening, or shallow sleep;
[0102] Concomitant symptoms: poor spirits, fatigue, shortness of breath and laziness to speak; loss of appetite or feeling full immediately after eating; weakness in the limbs; fullness and distension in the stomach, abdominal distension, constipation or loose stools; chest tightness; yellow or pale complexion; spontaneous sweating; pale red tongue with a distended body; deep, thin, slow or slippery pulse.
[0103] The main symptoms are required, and if two or more of the concomitant symptoms are present, the diagnosis can be made by referring to the tongue and pulse conditions.
[0104] 1.2 Inclusion and Exclusion Criteria
[0105] 1.2.1 Inclusion criteria
[0106] (1) Meet the above-mentioned Western medical diagnostic criteria for insomnia;
[0107] (2) Meet the diagnostic criteria of insomnia in traditional Chinese medicine;
[0108] (3) Meet the diagnostic criteria of spleen and stomach qi deficiency in traditional Chinese medicine.
[0109] 1.2.2 Exclusion criteria
[0110] (1) Patients with serious primary diseases such as cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system;
[0111] (2) People with severe mental illnesses such as organic psychosis, schizophrenia, and bipolar disorder.
[0112] 1.3 Case data collation and standardization methods
[0113] Since the original case data contained many non-standard problems such as inconsistent symptom terms, non-standard expressions of the four diagnoses, simplified diagnostic terms, and different expressions of the same medicine, two attending physicians of the Department of Psychology and Sleep at Guangdong Provincial Hospital of Traditional Chinese Medicine were asked to standardize the Western medicine diagnosis of outpatient cases while retaining the original case data and the ideas of diagnosis, treatment and medication. See Table 1 for details.
[0114] Table 1 Reference table for standardization of Western medicine diagnosis
[0115]
[0116] 1.4 Intervention measures
[0117] The sleeping and anti-anxiety decoction prepared in Example 2 is taken once a day, twice a day.
[0118] Western medicine: truthfully record the use of antipsychotics, mood stabilizers, antidepressants, and sedatives and hypnotics.
[0119] Treatment course: record truthfully.
[0120] 1.5 Main efficacy evaluation indicators
[0121] The Pittsburgh sleep quality index (PSQI) score change after treatment compared with the baseline was used for inter-group comparison and intra-group comparison.
[0122] 1.6 Data management and statistical analysis
[0123] All statistical data were processed using Microsoft Excel 2010 and IBM SPSS 22. Measurement data were expressed as x±s or M (P25, P75). The Shapiro-Wilk test was used to comprehensively determine whether the data conformed to the normal distribution. The independent sample t test was used to compare the measurement data that conformed to the normal distribution between the two groups. Nonparametric tests were used for measurement data that did not conform to the normal distribution. Count data were expressed as rate or percentage, and Fisher's exact probability method was used. P < 0.05 indicated that the difference was statistically significant.
[0124] 2. Results
[0125] 2.1 General Information
[0126] Among the 102 patients included, there were 30 males and 72 females; their ages ranged from 12 to 76 years old, with an average of (39.06±15.60) years old, and the average disease course was (68.70±76.30) months; 51 patients took sleeping and anti-anxiety decoctions (pure Chinese medicine group), and 51 patients used sleeping and anti-anxiety decoctions + Western medicine (Western medicine included antidepressants in 33 cases, sedatives and hypnotics in 16 cases, and mood stabilizers in 2 cases); the average number of doses of Chinese medicine taken was (12.96±5.79) doses.
[0127] 2.2 Efficacy of hypnotic and anti-anxiety drugs in the treatment of spleen deficiency type insomnia
[0128] 2.2.1 Overall efficacy
[0129] 102 patients were included. After treatment with the sleeping and anti-anxiety decoction, the total PSQI score of the patients after treatment (10.76±3.79 points) was reduced by 3.52 points (95% CI: 3.07-3.97) compared with the total PSQI score before treatment (14.28±3.64 points). The difference was statistically significant, t=15.438, P<0.001, as shown in Table 2. This shows that the sleeping and anti-anxiety drug of the present invention can effectively treat spleen deficiency type insomnia.
[0130] Table 2 Comparison of PSQI before and after treatment
[0131] n Before treatment After treatment Before and after difference t P 102 14.28±3.64 10.76±3.79 4.12±2.38 15.438 <0.001
[0132] 2.2.2 Efficacy of insomnia of different severity
[0133] According to the hierarchical treatment strategy of the Guidelines for the Clinical Diagnosis and Treatment of Insomnia Disorders (Insomnia) with Integrated Traditional Chinese and Western Medicine (T / GDACM0109-2022), patients were divided into different degrees of insomnia based on the total PSQI score before treatment. Patients with PSQI < 15 were classified as mild to moderate insomnia patients (called the mild to moderate group), and patients with PSQI ≥ 15 were classified as severe insomnia patients (called the severe group).
[0134] The PSQI of the two groups of patients after treatment was significantly lower than that before treatment (P < 0.05), and the degree of reduction in the severe group was more obvious than that in the mild and moderate group. The difference between the two groups before and after treatment was statistically significant (P < 0.05). See Table 3. This shows that the hypnotic and antianxiety drugs of the present invention have a good therapeutic effect on spleen deficiency type insomnia of different severity.
[0135] Table 3 Comparison of PSQI between the two groups before and after treatment
[0136] Group n Before treatment After treatment Before and after difference Mild to moderate group 51 11.20±2.72 8.55±2.72﹡ 2.64±2.42 Severe group 51 17.24±1.80 13.12±3.07﹟ 4.12±2.38 t -3.092 P 0.003
[0137] Note: Compared with the group before treatment, ﹡P<0.001(t=7.800), ﹟P<0.05(t=-4.843).
[0138] 2.2.3 Pure Chinese medicine efficacy
[0139] Because retrospective studies involve complex confounding factors such as the use of sedatives, hypnotics, antidepressants, and other intervention methods, 36 patients who had not used Western medicine before this visit or in any intervention method were further screened among the 102 patients included in this study to further clarify the efficacy of hypnotic and anti-anxiety drugs in the treatment of spleen deficiency-type insomnia.
[0140] After treatment with the sleeping and anti-anxiety decoction, the patient's total PSQI score after treatment (10.06±2.68 points) was reduced by 3.52 points (95% CI: 2.29-4.21) compared with the total PSQI score before treatment (13.31±3.37 points), and the difference was statistically significant, t=6.885, P<0.001, as shown in Table 4. This shows that the sleeping and anti-anxiety drug of the present invention can effectively treat spleen deficiency type insomnia.
[0141] Table 4 Comparison of PSQI before and after treatment
[0142] n Before treatment After treatment Before and after difference t P 36 13.31±3.37 10.06±2.68 3.25±2.83 6.885 <0.001
[0143] 2.3 Exploration of the characteristics of hypnotic and anti-anxiety drugs in the treatment of spleen deficiency type insomnia
[0144] 2.3.1 Improve the clinical efficacy of patients who have taken western medicine before diagnosis
[0145] 43 patients who had taken drugs with sedative and hypnotic effects, including antidepressants, sedatives, hypnotics, mood stabilizers, etc. before the intervention were screened (recorded as the group who had taken western medicine before diagnosis), of which 19 patients used antidepressants, 19 patients used sedatives, 1 patient used mood stabilizers, 3 patients used antidepressants combined with sedatives, and 1 patient used unknown medication. The total PSQI score of the patients was significantly lower after treatment than that before treatment in this group (P < 0.001), as shown in Table 5. This shows that the hypnotic and anti-anxiety drugs of the present invention can improve the clinical efficacy of patients who have taken western medicine before diagnosis.
[0146] Table 5 Comparison of PSQI before and after treatment in the group that had taken western medicine before diagnosis
[0147]
[0148] 2.3.2 Hypnotic and anti-anxiety drugs reduce the use of Western medicines
[0149] Looking back at the cases included in this study, it can be found that the sleeping and anti-anxiety decoction can reduce the types and dosages of psychiatric drugs in the original Western medicine treatment plan of 4 patients. The original Western medicine treatment plan of 4 patients can be discontinued and replaced with pure Chinese medicine treatment, as shown in Table 6.
[0150] Table 6: Hypnotic and anti-anxiety decoctions reduce the amount of Western medicine used
[0151]
[0152]
[0153] 2.4 Exploration of influencing factors of hypnotic and anti-anxiety drugs in the treatment of spleen deficiency type insomnia
[0154] 2.4.1 Whether to take Western medicine during the TCM intervention
[0155] According to the different intervention methods, the patients were divided into a pure Chinese medicine group (only taking hypnotic and anti-anxiety decoction, n=51) and a combined Chinese and Western medicine group (taking hypnotic and anti-anxiety decoction combined with sedative Western medicine such as antidepressants, sedatives, hypnotics, and mood stabilizers, n=51).
[0156] The PSQI of the two groups of patients after treatment was significantly lower than that before treatment (P < 0.001), and there was no statistically significant difference in the difference in PSQI between the two groups before and after treatment (P > 0.05), as shown in Table 7. The results show that the drugs taken by the two groups have significant effects on spleen deficiency insomnia, and there is no significant difference.
[0157] Table 7 Comparison of PSQI between the two groups before and after treatment
[0158]
[0159] Note: Compared with the group before treatment, ﹡P<0.001(t=8.953), ﹟P<0.001(t=10.401).
[0160] 2.4.2 Number of doses of Chinese medicine taken
[0161] In this study, Pearson correlation analysis was used to evaluate the relationship between the difference in total PSQI scores before and after treatment and the number of medication doses taken in patients with spleen deficiency-type insomnia.
[0162] Statistics show that there is a clear correlation between the difference in the total PSQI score before and after treatment and the number of medication doses taken, P = 0.014 < 0.05, see Table 8 for details. This result shows that the number of medication doses taken is proportional to the efficacy.
[0163] Table 8 Relationship between the difference in PSQI total score before and after treatment and the number of medication doses taken
[0164] n Before treatment After treatment Before and after difference Number of doses taken Person P 102 14.28±3.64 10.76±3.79 4.12±2.38 12.96±5.79 0.242 0.014
[0165] Test 2
[0166] 1. Research Plan
[0167] 1. Source of research cases
[0168] The cases selected for this study were all patients who visited the outpatient department of the Department of Psychology and Sleep at Guangdong Provincial Hospital of Traditional Chinese Medicine from October 2022 to February 2023. Inclusion and exclusion criteria were formulated, 25 cases were enrolled, 5 cases dropped out, and a total of 20 cases were included.
[0169] 2. Diagnostic criteria
[0170] 2.1 Western medicine diagnostic criteria
[0171] According to the diagnostic criteria for chronic insomnia disorder in the International Classification of Sleep Disorders (3rd edition) (ICSD-3) (2017 edition), the patient must meet all of the following: (1) to (6):
[0172] (1) The patient complains, or the parents or caregivers discover, one or more of the following symptoms:
[0173] Difficulty falling asleep.
[0174] Difficulty maintaining sleep.
[0175] Waking up earlier than you would like.
[0176] Refuse to go to bed on an appropriate schedule.
[0177] Difficulty falling asleep without intervention from a parent or caregiver.
[0178] (2) The patient complains, or the parents or caregivers discover, one or more of the following symptoms related to difficulty sleeping at night:
[0179] Fatigue and malaise.
[0180] Impaired attention, concentration and memory.
[0181] Social, family, and occupational functioning are impaired, and academic performance declines.
[0182] Mood swings or irritability.
[0183] Daytime sleepiness.
[0184] Behavioral problems (such as hyperactivity, impulsiveness, or aggressive behavior).
[0185] Low enthusiasm, energy, or motivation.
[0186] Increased tendency to errors and accidents.
[0187] Excessive concern or dissatisfaction with sleep.
[0188] (3) The complaint of difficulty sleeping / awakening cannot be simply explained by insufficient sleep opportunity (e.g., sufficient sleep time allocated) or a poor sleeping environment (e.g., safe, dark, quiet, and comfortable environment).
[0189] (4) Sleep disturbances and related daytime symptoms occur at least three times a week.
[0190] (5) Sleep disturbance and related daytime symptoms persist for at least 3 months.
[0191] (6) The sleep / wake difficulty is not better explained by another sleep disorder.
[0192] 2.2 Standards of TCM Syndrome Differentiation
[0193] With reference to the relevant discussions in "Treatise on Spleen and Stomach", the Huangqi Renshen Decoction syndrome is proposed to be the spleen and stomach qi deficiency syndrome, and the TCM syndrome differentiation standard is formulated with reference to the spleen and stomach qi deficiency syndrome in the "Terminology of Clinical Diagnosis and Treatment of Traditional Chinese Medicine" and the "Guidelines for Clinical Trials of New Chinese Medicines for the Treatment of Insomnia".
[0194] Diagnostic criteria:
[0195] Main symptoms: early awakening, difficulty falling asleep, easy awakening, or shallow sleep;
[0196] Associated symptoms: poor spirits, fatigue, shortness of breath and laziness; loss of appetite or feeling full immediately after eating; weakness in the limbs; fullness and distension in the stomach, abdominal distension, constipation or loose stools; chest tightness; yellow or pale complexion; spontaneous sweating; pale red tongue with a distended base; deep, thin, slow or slippery pulse.
[0197] The main symptoms are required, and if two or more of the concomitant symptoms are present, the diagnosis can be made by referring to the tongue and pulse conditions.
[0198] 3. Inclusion criteria
[0199] (1) Meet the above-mentioned Western medical diagnostic criteria for insomnia;
[0200] (2) Sleep latency > 30 minutes, and / or, number of nighttime awakenings ≥ 2 times / night, and / or, total sleep time < 6 hours, and the above three sleep disorder symptoms occur ≥ 3 times per week and last for ≥ 28 days;
[0201] (3) Meet the diagnostic criteria of insomnia in traditional Chinese medicine;
[0202] (4) Meet the syndrome differentiation criteria of spleen and stomach qi deficiency in traditional Chinese medicine;
[0203] (5) Age 18-65 years old;
[0204] (6) Vital signs are stable, the patient is conscious, and has a certain level of expression and cognitive ability;
[0205] (7) No sedatives, hypnotics, antipsychotics, antibiotics, glucocorticoids, or other drugs were taken in the past 2 weeks;
[0206] (8) Those who are willing to participate in the study and sign the informed consent.
[0207] 4. Exclusion criteria
[0208] (1) Those who do not meet the inclusion criteria;
[0209] (2) Patients with secondary insomnia caused by systemic diseases such as pain, fever, cough, surgery, etc., as well as external environmental interference factors;
[0210] (3) Pregnant or lactating women or women planning to become pregnant;
[0211] (4) patients with a history of organic digestive tract disease or gastrointestinal surgery;
[0212] (5) Those whose work and living environment cannot guarantee a fixed residence and adequate sleep opportunities (at least 8 hours of bedtime); those who have worked or lived in three or more time zones in the past 7 days;
[0213] (6) Participated in other clinical trials in the past three months;
[0214] (7) Patients with insomnia and comorbid depression, anxiety, or other mental disorders;
[0215] (8) Patients with serious primary diseases such as cardiovascular, cerebrovascular, lung, liver, kidney and hematopoietic system;
[0216] (9) Patients with depression, anxiety, schizophrenia and other serious mental disorders, or those with a history of mental disorders;
[0217] (10) Patients with other sleep disorders such as sleep apnea and restless legs syndrome;
[0218] (11) Alcoholics and / or psychoactive drug users, drug abusers and drug addicts;
[0219] (12) Patients with serious primary diseases such as cardiovascular, cerebrovascular, pulmonary, liver, kidney and hematopoietic system diseases.
[0220] 5. Elimination criteria
[0221] ① If allergic reactions or serious adverse events occur, the trial should be stopped according to the doctor's judgment.
[0222] ② During the trial, the patient develops other diseases that affect the judgment of efficacy and safety.
[0223] ③ Subjects with poor compliance, or who automatically change medication midway or add Chinese and Western medicines prohibited by this protocol (the time of medication change is considered as dropout).
[0224] ④ Those who are found to seriously violate the inclusion criteria after enrollment.
[0225] ⑤ Those who did not take the trial drug after enrollment.
[0226] 6. Intervention measures
[0227] The sleeping and anti-anxiety decoction prepared in Example 3.
[0228] Usage: One dose per day, taken twice a day with warm water. Intervention duration: 2 weeks.
[0229] Rescue medication during the study: Zolpidem tablets, 10 mg. ① Conditions of use: During the study, if the subject still cannot fall asleep 1 hour after going to bed and cannot tolerate insomnia, Zolpidem tablets can be taken as a rescue medication. ② Dosage: 10 mg / time, up to 3 times a week. ③ Notes: When the subject takes Zolpidem tablets, please be sure to record it in detail in the sleep diary. When the subject takes Zolpidem tablets, it is considered a withdrawal case.
[0230] 7. Efficacy indicators
[0231] (1) Sleep quality
[0232] Pittsburgh Sleep Quality Index (PSQI) score: baseline and at the end of treatment.
[0233] (2) Psychosomatic symptoms:
[0234] Cornell Medical Index (CMI) score: baseline and at the end of treatment.
[0235] 8. Statistical analysis
[0236] The statistical analysis of this study was calculated using SPSS13.0 statistical analysis software. The counting indicators were statistically described using frequency and composition ratio, and the measurement data were statistically described using x±s. Effectiveness analysis: The scale scores before and after treatment were compared using paired t-tests. Hypothesis tests were all bilateral, with P<0.05 as statistically significant and P<0.01 as statistically significant.
[0237] 2. Research Results
[0238] 1. Case completion status
[0239] A total of 25 cases were included in this clinical study, 20 cases were actually completed, 5 cases dropped out, and finally 20 cases were completed, with a completion rate of 80%.
[0240] 2. Comparison of sleep quality before and after treatment
[0241] The comparison results of PSQI before and after treatment are shown in Table 9. It can be seen from Table 9 that the PSQI score after treatment was significantly lower than that before treatment, and P < 0.01, the difference is statistically significant.
[0242] Table 9 Comparison of PSQI before and after treatment
[0243]
[0244] 3. Comparison of physical and mental symptoms before and after treatment
[0245] 3.1 Comparison of total CMI scores before and after treatment
[0246] The comparison results of the total CMI scores before and after treatment are shown in Table 10. As can be seen from Table 10, the total CMI score after treatment was significantly lower than that before treatment, and P < 0.01, the difference is statistically significant.
[0247] Table 10 Comparison of CMI before and after treatment
[0248]
[0249] 3.2 Comparison of MR (emotional score) of CMI before and after treatment
[0250] The comparison results of the MR scores of CMI before and after treatment are shown in Table 11. It can be seen from Table 11 that the emotional score of CMI after treatment was significantly lower than that before treatment, and P < 0.01, the difference is statistically significant.
[0251] Table 11 Comparison of MR scores of CMI before and after treatment
[0252]
[0253] 4. Conclusion
[0254] In summary, the sleeping and anti-anxiety decoction of the present invention is used to treat chronic insomnia of spleen deficiency type. Before and after treatment, the patient's Pittsburgh Sleep Quality Index (PSQI) score and Cornell Medical Index (CMI) total score and emotional score are all reduced, and the difference is statistically significant. It shows that the sleeping and anti-anxiety drug of the present invention can effectively improve the sleep quality and psychosomatic symptoms of patients with chronic insomnia of spleen deficiency type.
[0255] The above are only some embodiments of the present invention. For those skilled in the art, several modifications and improvements can be made without departing from the creative concept of the present invention, which all belong to the protection scope of the present invention.
Claims
1. A sleeping and anti-anxiety drug, It is characterized in that The effective ingredients include the following raw materials in parts by weight: 10-50 parts of astragalus, 10-15 parts of cimicifuga, 10-30 parts of codonopsis, 10-30 parts of tangerine peel, 10-30 parts of ophiopogon, 10-30 parts of atractylodes, 10-30 parts of white atractylodes, 5-45 parts of phellodendron, 10-50 parts of Shenqu, 5-20 parts of angelica, 5-30 parts of liquorice, 5-15 parts of schisandra, 10-30 parts of alpinia oxyphylla, 5-30 parts of bitter almond, 5-30 parts of dried ginger, 10-20 parts of peony bark, and 10-30 parts of anemarrhena.
2. The hypnotic and antianxiety drug according to claim 1, It is characterized in that Its effective ingredients include the following raw materials in parts by weight: 30 parts of astragalus, 15 parts of cimicifuga, 15 parts of codonopsis, 15 parts of tangerine peel, 15 parts of ophiopogon, 15 parts of atractylodes, 15 parts of white atractylodes, 10 parts of phellodendron, 30 parts of Shenqu, 10 parts of angelica, 15 parts of liquorice, 10 parts of schisandra, 15 parts of alpinia oxyphylla, 15 parts of bitter apricot, 5 parts of dried ginger, 15 parts of peony bark, and 15 parts of anemarrhena.
3. The hypnotic and antianxiety drug according to claim 1 or 2, It is characterized in that The effective ingredients also include at least one of the following raw materials in parts by weight: 15-30 parts of Angelica dahurica, 5-10 parts of Notopterygium wilfordii, 5-10 parts of Saposhnikovia divaricata, 15-30 parts of Radix Rehmanniae, 15-30 parts of Gypsum, 30-60 parts of Radix Trichosanthis, 15-30 parts of Magnolia officinalis, and 15-30 parts of Apricot kernel.
4. The hypnotic and antianxiety drug according to claim 1 or 2, It is characterized in that The licorice is roasted licorice.
5. The hypnotic and antianxiety drug according to claim 1 or 2, It is characterized in that Pharmaceutically acceptable excipients may also be added.
6. The hypnotic and antianxiety drug according to claim 5, It is characterized in that The auxiliary material is at least one of a sustained-release agent, an excipient, a filler, a binder, a wetting agent, a disintegrant, an absorption promoter, an adsorption carrier, a surfactant, and a lubricant.
7. The hypnotic and antianxiety drug according to claim 1 or 2, It is characterized in that The dosage form of the medicine is granules, decoction, paste, powder, tablet, pill or capsule.
8. A method for preparing the hypnotic and antianxiety drug according to any one of claims 1 to 7, It is characterized in that When the dosage form of the drug is granules, the preparation method thereof comprises the following steps: (1) The above raw material drug is decocted with water twice. For the first decoction, water equivalent to 10 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and the first decoction and the residue are obtained after separation; for the second decoction, the residue obtained after the first decoction is taken, water equivalent to 8 times the total weight of the raw material drug is added, heated to boiling, and kept at a slight boiling for 1.5 hours, and the second decoction and the residue are obtained after separation; the first decoction and the second decoction are combined and filtered to obtain a filtrate; (2) concentrating the obtained filtrate under reduced pressure to obtain a clear paste; (3) adding auxiliary materials to the obtained clear paste and spray drying to obtain dry paste powder, wherein the spray drying process parameters are: inlet air temperature 165-185° C., outlet air temperature 80-95° C.; (4) adding auxiliary materials to the obtained dry paste powder and mixing them evenly to obtain a mixed powder; (5) adding a 90% by volume ethanol-water solution to the obtained mixed powder to prepare a soft material, and granulating the soft material through a 12-mesh sieve to obtain wet granules; (6) Dry the obtained wet granules at 65°C to obtain the product.
9. Use of the hypnotic and antianxiety drug according to any one of claims 1 to 7 in the preparation of a drug for treating spleen deficiency type insomnia and / or anxiety and / or depression.
10. Use of the hypnotic and antianxiety drug according to any one of claims 1 to 7 in the preparation of a drug for treating chronic insomnia and / or anxiety and / or depression of spleen deficiency type.
Citation Information
Patent Citations
Astragalus atractylodes decoction
CN101062159A
Cited By
Traditional Chinese medicine composition for treating juvenile depressive disorder caused by insufficient fluid blood and deficiency-heat internal disturbance as well as preparation method and application of traditional Chinese medicine composition
CN119770607A
